氟轻松玻璃体内植入剂(ILUVIEN)的安全性与有效性:欧洲IRISS注册研究3年结果
IRISS是一项多中心、开放标签、非随机、观察性4期研究,评估氟轻松玻璃体内植入剂在欧洲真实实践中的安全性和有效性。695只眼(556例患者)接受植入,96.7%为慢性糖尿病性黄斑水肿(cDMO),平均随访1150.5±357.36天;36个月时平均视力从基线52.2个字母提高到57.1个字母,结论认为该植入剂在cDMO眼中具有有利的长期获益-风险特征,早期给药有额外获益。
要点
- 695只眼接受氟轻松玻璃体内植入剂,96.7%为慢性糖尿病性黄斑水肿。
- 36个月时平均视力从基线52.2个字母提高到57.1个字母,改善持续至48个月。
- 34.5%的眼使用局部药物、4.3%通过手术降低眼压;113只晶状体眼中73只(64.6%)需白内障手术。
核心结论
- 本研究证实氟轻松玻璃体内植入剂在慢性糖尿病性黄斑水肿眼中具有有利的长期获益-风险特征,早期给药患者有额外获益。
研究设计与样本
- 多中心、开放标签、非随机、观察性4期研究,纳入2013年至2017年间接受氟轻松玻璃体内植入剂的患者,监测至最后一位患者随访≥3年。
- 纳入695只眼(556例患者),平均±标准差随访1150.5±357.36天,数据包括前瞻性和回顾性收集。
主要发现
- 96.7%的眼为慢性糖尿病性黄斑水肿。
- 34.5%的眼使用局部药物降低眼压,4.3%的眼通过手术降低眼压。
- 113只晶状体眼中73只(64.6%)在随访期间需白内障手术。
- 平均视力从基线52.2个字母提高到36个月时57.1个字母,改善持续至48个月。
- 43.7%的眼接受了补充治疗;按cDMO病程长短(以中位病程分为短于和长于中位)分类,病程较短者视力获益大于病程较长者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The ILUVIEN Registry Safety Study was a multicentre, open-label, non-randomised, observational, phase 4 study designed to assess the safety and effectiveness of the fluocinolone acetonide (FAc) implant in all indications in real-world practices in Europe. METHODS: The study included data collected prospectively and retrospectively. Patients receiving FAc implants between 2013 and 2017 were included and monitored until the last patient reached ≥3 years of follow-up. Mean intraocular pressure (IOP) data over the course of the study, along with IOP events, use of IOP-lowering therapy, mean change in visual acuity (VA) and information on supplemental therapy use were analysed post-FAc implantation. RESULTS: Six hundred and ninety-five eyes from 556 patients, with a mean±SD follow-up of 1150.5±357.36 days, were treated with a FAc implant. 96.7% of eyes had chronic diabetic macular oedema (cDMO). IOP lowering was achieved in 34.5% of eyes using topical agents and 4.3% by surgery. Seventy-three eyes (64.6% of 113 phakic) required cataract surgery during follow-up. Mean VA increased from a baseline of 52.2 letters to 57.1 letters at month 36, with improvement observed up to month 48. Supplementary therapies were given in 43.7% of eyes. When classified by length of cDMO less than or greater than the median duration those with a shorter history experienced greater VA gains than those with a longer history. CONCLUSION: This study confirms the favourable, long-term benefit-to-risk profile of the FAc implant in eyes with cDMO, with an additional benefit in patients when this therapy is administered earlier.
引用
- Khoramnia R, Peto T, Koch F, et al. Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study. Br J Ophthalmol. 2022. PMID: 35840291. doi:10.1136/bjo-2022-321415
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。